title: Process monitoring of an HIV treatment as prevention program in British Columbia, Canada.
abstract: BACKGROUND
  In light of accumulated scientific evidence of the secondary preventive benefits of antiretroviral therapy, a growing number of jurisdictions worldwide have formally started to implement HIV Treatment as Prevention (TasP) programs. To date, no gold standard for TasP program monitoring has been described. Here, we describe the design and methods applied to TasP program process monitoring in British Columbia (BC), Canada.
  
  
  METHODS
  Monitoring indicators were selected through a collaborative and iterative process by an interdisciplinary team including representatives from all 5 regional health authorities, the BC Centre for Disease Control (BCCDC), and the BC Centre for Excellence in HIV/AIDS (BC-CfE). An initial set of 36 proposed indicators were considered for inclusion. These were ranked on the basis of 8 criteria: data quality, validity, scientific evidence, informative power of the indicator, feasibility, confidentiality, accuracy, and administrative requirement. The consolidated list of indicators was included in the final monitoring report, which was executed using linked population-level data.
  
  
  RESULTS
  A total of 13 monitoring indicators were included in the BC TasP Monitoring Report. Where appropriate, indicators were stratified by subgroups of interest, including HIV risk group and demographic characteristics. Six Monitoring Reports are generated quarterly: 1 for each of the regional health authorities and a consolidated provincial report.
  
  
  CONCLUSIONS
  We have developed a comprehensive TasP process monitoring strategy using evidence-based HIV indicators derived from linked population-level data. Standardized longitudinal monitoring of TasP program initiatives is essential to optimize individual and public health outcomes and to enhance program efficiencies.
authors: *British Columbia Centre for Excellence in HIV/AIDS, Providence Health Care, Vancouver, Canada; †Division of AIDS, Department of Medicine, University of British Columbia, Vancouver, Canada; ‡Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada; §British Columbia Centre for Disease Control, Vancouver, Canada; ‖Vancouver Coastal Health Authority, Vancouver, Canada; ¶Fraser Health Authority, Surrey, Canada; #First Nations Health Authority, West Vancouver, Canada; **Interior Health Authority, Kelowna, Canada; ††Northern Health Authority, Prince George, Canada; ‡‡Oak Tree Clinic, Provincial Health Services Authority, Vancouver, Canada; and §§Vancouver Island Health Authority, Victoria, Canada.
authors: Lillian
authors: L
authors: Lourenço
authors: Viviane D
authors: VD
authors: Lima
authors: Kate
authors: K
authors: Heath
authors: Bohdan
authors: B
authors: Nosyk
authors: Mark
authors: M
authors: Gilbert
authors: Guillaume
authors: G
authors: Colley
authors: Theodora
authors: T
authors: Consolacion
authors: Rolando
authors: R
authors: Barrios
authors: Robert
authors: R
authors: Hogg
authors: Mel
authors: M
authors: Krajden
authors: Stephanie
authors: S
authors: Konrad
authors: Michelle
authors: M
authors: Murti
authors: Joanne
authors: J
authors: Nelson
authors: Jennifer
authors: J
authors: May-Hadford
authors: James
authors: J
authors: Haggerstone
authors: Neora
authors: N
authors: Pick
authors: Reka
authors: R
authors: Gustafson
authors: Melanie
authors: M
authors: Rusch
authors: Irene
authors: I
authors: Day
authors: Julio S G
authors: JS
authors: Montaner
mesh_terms: D023241:Antiretroviral Therapy, Highly Active; D001955:British Columbia; D018791:CD4 Lymphocyte Count; D019317:Evidence-Based Medicine; D015658:HIV Infections / Q000188:drug therapy / Q000276:immunology / Q000517:prevention & control* / Q000821:virology; D006801:Humans; D015397:Program Evaluation; D019984:Quality Indicators, Health Care / Q000592:standards*; D019562:Viral Load